Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 8:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sweating Clear all
Completed Phase 4 Interventional Results available

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

NCT02808975
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Placebo, Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Beverly Hills, California • Encino, California • Irvine, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Jul 21, 2026, 8:20 PM EDT
Terminated Not applicable Interventional

A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis

NCT01722461
View directory record Official record
Conditions
Primary Axillary Hyperhidrosis
Interventions
Ulthera System, Sham treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Roseville, California • Aventura, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Jul 21, 2026, 8:20 PM EDT
Not yet recruiting Phase 2 Interventional

Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

NCT07689188
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Roflumilast 0.3% topical foam
Drug
Lead sponsor
Harrison Dermatology
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Missouri City, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 8:20 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

NCT04092452
View directory record Official record
Conditions
Acne Inversa
Interventions
PF-06650833, PF-06700841, PF-06826647, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
63
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 21, 2026, 8:20 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04988308
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bermekimab, Adalimumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Phoenix, Arizona • Fountain Valley, California • Fremont, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Jul 21, 2026, 8:20 PM EDT
Active, not recruiting Phase 2 Interventional

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma, Carcinoma Arising From Spiradenoma, Digital Papillary Adenocarcinoma, Endocrine Mucin-Producing Sweat Gland Carcinoma, Extramammary Paget Disease, Extraocular Sebaceous Carcinoma, Hidradenocarcinoma, Malignant Sweat Gland Neoplasm, Merkel Cell Carcinoma, Microcystic Adnexal Carcinoma, NK-Cell Lymphoma, Unclassifiable, Papillary Adenocarcinoma, Porocarcinoma, Primary Cutaneous Mucinous Carcinoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Merkel Cell Carcinoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Skin Squamous Cell Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Signet Ring Cell Adenocarcinoma, Skin Adenoid Cystic Carcinoma, Skin Adnexal Carcinoma, Skin Basal Cell Carcinoma, Skin Basosquamous Cell Carcinoma, Skin Keratoacanthoma, Skin Squamous Cell Carcinoma, Squamoid Eccrine Ductal Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Sweat Gland Carcinoma, Trichilemmal Carcinoma, Vulvar Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Nivolumab, Positron Emission Mammography, Talimogene Laherparepvec
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
36
States / cities
Los Angeles, California • Orange, California • Pasadena, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 21, 2026, 8:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser

NCT03054155
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Alexandrite Laser
Device
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Jul 21, 2026, 8:20 PM EDT
Recruiting Phase 2 Interventional

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

NCT07228390
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 8:20 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03713632
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
15
States / cities
San Diego, California • Whittier, California • Coral Gables, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 21, 2026, 8:20 PM EDT
Completed Phase 2 Interventional

Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa

NCT02695212
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Apremilast
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Jul 21, 2026, 8:20 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 8:20 PM EDT
Completed Not applicable Interventional Results available

Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa

NCT04600375
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Verbal consultation, Written Action Plan
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 89 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Jul 21, 2026, 8:20 PM EDT
Withdrawn Phase 4 Interventional

Botulinum Toxin-A for Hidradenitis Suppurativa

NCT06237465
View directory record Official record
Conditions
Hidradenitis Suppurativa, Hidradenitis Suppurativa \(HS\), Hidradenitis Suppurativa, Acne Inversa
Interventions
Normal saline, Botulinum toxin type A
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Guilford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jul 21, 2026, 8:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

NCT00795574
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
infliximab, Placebo Comparator
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
16 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2008 · Synced Jul 21, 2026, 8:20 PM EDT
Completed Not applicable Interventional

Prosthetic Socket Interface Design on Socket Comfort, Residual Limb Health, and Function for the Transfemoral Amputee

NCT02773056
View directory record Official record
Conditions
Amputation
Interventions
Ischial Ramus Containment (IRC), Dynamic Socket Ischial Ramus Containment (IRC), Sub-Ischial Interface (Sub-I)
Device
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 44 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Jul 21, 2026, 8:20 PM EDT
Completed Phase 1 Interventional

Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis

NCT00219882
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
standardized turmeric root extract
Drug
Lead sponsor
Ramsey, Bonnie, MD
Individual
Eligibility
18 Years to 40 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Jul 21, 2026, 8:20 PM EDT
Completed Not applicable Interventional Results available

Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating

NCT04599907
View directory record Official record
Conditions
Primary Axillary Hyperhidrosis
Interventions
Roll-In Cohort: Single Application of N-SWEAT Patch, Randomized Cohort: Single Application of N-SWEAT Patch, Randomized Cohort: Single Application of Sham Patch
Device
Lead sponsor
Candesant Biomedical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Encinitas, California • Fremont, California • Rockville, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Jul 21, 2026, 8:20 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06411899
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Sonelokimab, Placebo
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
36
States / cities
Los Angeles, California • Northridge, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 21, 2026, 8:20 PM EDT
Completed Not applicable Interventional Results available

Management of Palmar Hyperhidrosis With Hydrogel-based Iontophoresis

NCT02854540
View directory record Official record
Conditions
Hyperhidrosis, Hyperhidrosis Palmaris et Plantaris
Interventions
Hydrogel electrode-based iontophoresis
Device
Lead sponsor
Stanford University
Other
Eligibility
13 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Palo Alto, California • Redwood City, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Jul 21, 2026, 8:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Evaluate the Efficacy of Bite's Natural Deodorant

NCT05503784
View directory record Official record
Conditions
Sweat, Underarm Odor
Interventions
BITE Deodorant
Other
Lead sponsor
Kind Lab PBC.
Industry
Eligibility
24 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Jul 21, 2026, 8:20 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

NCT06524635
View directory record Official record
Conditions
Hidradenitis Suppurativa, Atopic Dermatitis
Interventions
Lutikizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Sacramento, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Jul 21, 2026, 8:20 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT03827798
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 21, 2026, 8:20 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa

NCT04582669
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Intralesional Triamcinolone 10 mg/mL, Intralesional Triamcinolone 20 mg/mL, Intralesional Triamcinolone 40 mg/mL, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
13 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Jul 21, 2026, 8:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Methods of Assessing Sweat-Electrolyte Testing (MAST)

NCT07490756
View directory record Official record
Conditions
Sweat Sodium Concentration
Interventions
Wearing the hDrop hydration sensor
Device
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 21, 2026, 8:20 PM EDT